Significant events in the fourth quarter
· A rights issue underwritten to 100% was completed in November, and generated net proceeds of MSEK 28.3 for
Significant events during the period
· A rights issue underwritten to 88% was completed in March, and generated net proceeds of MSEK 20.6 for
· In March, disbursements from the EU's Horizon 2020 programme were resumed and KEUR 550 was paid out.
· In June,
· In June, it was announced that the manufacturing process for the company's tolerogenic cell therapy had been successfully established at
· Åsa Schiött was appointed new Chief Scientific Officer (CSO),
· In September,
Significant events after the end of the period
· No other significant events occurred after the end of the period that affected the results or financial position.
Financial information of the fourth quarter (October-
· Other operating income amounted to KSEK 1,949 (1,225)
· Operating loss was KSEK -7,449 (-8,005)
· Loss for the period totalled KSEK -7,897 (-8,207)
· Cash flow from operating activities was KSEK -10,428 (-7,790)
· Loss per share before dilution was
· The proposed dividend is
Financial information of the period (January-
· Other operating income amounted to KSEK 8,113 (4,192)
· Operating loss was KSEK -26,153 (-32,826)
· Loss for the period totalled KSEK -26,822 (-32,694)
· Cash flow from operating activities was KSEK -28,081 (-34,974)
· Loss per share before dilution was
If you have any questions, please contact:
Phone: +46 (0) 709 18 00 10
E-mail: anders.karlsson@idogen.com
This year-end report has been approved by the Board of Directors and the CEO for publication. The information was submitted, through the care of the above contact person, for publication on
Certified Adviser:
Phone: +46 (0)8-463 80 00
E-mail: certifiedadviser@penser.se
https://news.cision.com/idogen/r/idogen-publishes-year-end-report-for-2020,c3282521
https://mb.cision.com/Main/12368/3282521/1369778.pdf
https://mb.cision.com/Public/12368/3282521/b1b7c61faea00726.pdf
(c) 2021 Cision. All rights reserved., source